Esketamine

證據等級: L5

預測適應症: 10 個

Esketamine: From Treatment-Resistant Depression to Agoraphobia

One-Sentence Summary

Esketamine (Spravato) is the S-enantiomer of ketamine, an NMDA receptor antagonist approved in the United States and European Union for treatment-resistant depression (TRD), but not currently registered on the Australian Register of Therapeutic Goods (ARTG). The TxGNN model predicts it may be effective for Agoraphobia, with 0 clinical trials and 1 publication currently supporting this specific direction. While the prediction score is high (99.57%), the evidence linking esketamine to agoraphobia remains indirect — drawing on anxiety spectrum mechanistic inference rather than validated clinical data.

Quick Overview

Item	Content
Original Indication	Treatment-resistant depression (FDA/EMA-approved 2019; not currently registered in Australia)
Predicted New Indication	Agoraphobia
TxGNN Prediction Score	99.57%
Evidence Level	L4
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the Evidence Pack. Based on known information from the published literature, esketamine acts primarily as a non-competitive NMDA (N-methyl-D-aspartate) receptor antagonist. Its rapid antidepressant effects are thought to involve NMDA receptor blockade triggering a synaptic glutamate surge, which activates AMPA receptors, initiates the mTORC1 and BDNF/TrkB signalling cascade, and restores synaptic plasticity — particularly in the medial prefrontal cortex — within hours. This mechanism is fundamentally distinct from conventional monoamine-based antidepressants.

Agoraphobia is characterised by intense fear and avoidance of situations perceived as difficult to escape, with cognitive-behavioural mechanisms as its primary pathology. The amygdala plays a central role in fear memory encoding and extinction, and glutamatergic neurotransmission within the amygdala-prefrontal fear circuit is well established. NMDA receptor activity is required for both fear memory consolidation and extinction learning. In theory, modulation of this circuit by esketamine could influence fear-based anxiety conditions, including agoraphobia.

However, the mechanistic link between NMDA receptor antagonism and agoraphobia specifically remains indirect and unvalidated. The TxGNN knowledge graph likely captures a broad “anxiety spectrum” node connection rather than a direct pharmacological or clinical pathway. There is no published preclinical or clinical evidence specifically evaluating esketamine for agoraphobia, and the condition’s primary treatment remains cognitive-behavioural therapy (CBT) combined with SSRIs or SNRIs. The high TxGNN score should therefore be interpreted with caution.

Clinical Trial Evidence

Currently no related clinical trials registered for Esketamine in agoraphobia.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
33424664	2020	Narrative Review	Frontiers in Psychiatry	Comprehensive review of pharmacotherapy for anxiety disorders (panic disorder, GAD, social anxiety disorder, agoraphobia); discusses glutamatergic agents including ketamine and esketamine as emerging treatment options across the anxiety spectrum, noting a relative dearth of novel medications specifically targeting anxiety disorders compared to depression

Australia Market Information

Esketamine is not currently registered on the Australian Register of Therapeutic Goods (ARTG). No approved products, licensed indications, or dosage form entries exist in Australia. Any proposed clinical use would require either a TGA Special Access Scheme (SAS) application or a Clinical Trial Notification (CTN) submission. Internationally, esketamine nasal spray (Spravato, 56 mg and 84 mg) holds approval in the US (FDA, 2019), EU (EMA, 2019), and multiple other jurisdictions for treatment-resistant depression and major depressive disorder with acute suicidal ideation or behaviour.

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information. As esketamine is not registered in Australia, clinicians should consult the FDA or EMA-approved prescribing information (PI/SmPC for Spravato) for comprehensive safety data. Key considerations known from the international literature include:

Risk of dissociation, dizziness, and sedation: Esketamine carries a Risk Evaluation and Mitigation Strategy (REMS) requirement in the US; patients must be monitored for at least two hours post-dose in a certified healthcare setting
Abuse and misuse potential: Ketamine and esketamine have Schedule 8 (controlled drug) status or equivalent in most jurisdictions; diversion and misuse risk must be considered
Cardiovascular effects: Transient increases in blood pressure and heart rate have been documented; caution in patients with unstable cardiovascular disease
Dissociative effects: Perceptual disturbances and dissociation are common acute adverse effects

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a very high TxGNN prediction score (99.57%), the evidence base for esketamine in agoraphobia is limited to a single indirect narrative review (L4), with no clinical trials registered and no mechanism-specific preclinical data. Agoraphobia’s primary pathophysiology is cognitive-behavioural and serotonergic rather than glutamatergic, and the drug is not currently available in Australia.

To proceed, the following is needed:

Mechanistic evidence: Preclinical studies in validated animal models of contextual fear or agoraphobia-like avoidance to establish proof of concept for NMDA receptor antagonism
Pharmacological rationale: MOA data confirming esketamine’s effects on amygdala fear circuits, fear memory reconsolidation, and extinction learning beyond its antidepressant mechanism
Clinical data: At minimum, a pilot observational study or Phase 2 RCT evaluating esketamine in anxiety spectrum disorders with agoraphobia as a defined outcome
Regulatory pathway: Assessment of TGA Special Access Scheme (SAS Category B/C) or Clinical Trial Notification pathway, given the drug’s unapproved status in Australia
Safety profiling: Evaluation of esketamine’s dissociative and sympathomimetic effects in an anxiety-disorder population, who may have heightened sensitivity to perceptual disturbances

Note for clinicians: While the evidence for agoraphobia (Rank 1) is insufficient to support clinical action at this stage, it is worth noting that the same Evidence Pack contains substantially stronger data for depression-spectrum conditions. Neurotic depression (Rank 3, L1 evidence, 20 publications including multiple Phase 3 RCTs) and insomnia (Rank 8, L2 evidence, 46 clinical trials, multiple completed RCTs) represent more clinically actionable directions that may warrant separate evaluation if esketamine were to be pursued for an Australian access pathway.

This report is generated for research reference purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before therapeutic application. For Australian prescribing information, consult the TGA and relevant regulatory guidelines.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.